Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$17.44 - $23.16 $241,561 - $320,789
-13,851 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$17.03 - $22.67 $235,882 - $314,002
13,851 New
13,851 $311,000
Q3 2020

Nov 13, 2020

SELL
$20.67 - $26.94 $112,486 - $146,607
-5,442 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$16.46 - $27.42 $53,034 - $88,347
3,222 Added 145.14%
5,442 $129 Million
Q1 2020

May 15, 2020

BUY
$14.46 - $21.8 $32,101 - $48,396
2,220 New
2,220 $38,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.6B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Fora Capital, LLC Portfolio

Follow Fora Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fora Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fora Capital, LLC with notifications on news.